We believe that Medtronic (MDT) is a high quality company with a Business Quality Score of 7 based on a scale of 1 to 10 (10 is best). Also, shares of Medtronic appear to be undervalued based on a discounted cash flow analysis. Medtronic stock would need to rise 26.7% to reach fair value based on the closing price of $43.88/share for shares on 02-25-2013.
Business Quality Analysis:
Medtronic has a Business Quality Score of 7 out of 10 based on an analysis of historical data. We assign a Business Quality Score to each company undergoing analysis. The score is based on a scale of 1 to 10 with a value of 10 indicating the best possible Business Quality Score. Our Business Quality Score is a proprietary metric which takes into account the 10-year historical performance of the company. Performance is measured considering the absolute performance (and trends) in revenues, earnings, profit margins, and returns on assets/equity.
Low Business Quality Scores (3 or lower) indicate companies that are in a cyclical or commodity business. These businesses have erratic revenues and earnings with associated low profit margins and poor returns on capital. Low quality companies operate in highly competitive/cyclical businesses where consistent profits are nearly impossible to achieve.
Medium Business Quality Scores (4 to 6) indicate an average quality business that operates in a business environment that is not overly cyclical in nature. Also, the products or services these businesses provide are not yet commoditized but do operate in a highly competitive business environment. Moreover, these businesses do not have durable competitive advantages that will allow these businesses to earn consistently high returns on capital. Companies with a medium Business Quality Score can sometimes be good investments if bought at deeply discount prices and sold at fair value. This is in contrast to investments in businesses with high Business Quality Scores where paying fair value for shares can yield good returns if held for the long term.
High Business Quality Scores (7 or higher) indicate companies that are in high quality businesses with some type of durable competitive advantages that keep competitors at bay. These businesses typically have steadily rising revenues and earnings with associated high profit margins and high returns on capital.
Medtronic's revenues have had great performance over the last 10 years growing at a compound annual growth rate of 7.8%. Revenues grew in every year during the period. Overall, we are very pleased with Medtronic's revenue performance. We believe that Medtronic will grow revenues at a 5.5% compound annual growth rate over the next decade.
Earnings Per Share:
Medtronic's earnings grew at a compound annual growth rate of 9.5% over the last decade. However, earnings declined in 3 out of 10 years with a 7.5% decline in 2005, 19.1% decline in 2008 and a 1.0% decline in 2009. The overall trend in earnings is good but we would like to see earnings increase every year. Medtronic's earnings performance could be significantly better and this is one reason Medtronic's Business Quality Score is not higher than 7. We believe that Medtronic's earnings will grow at a 7.5% compound annual growth rate in the coming years.
A company's earnings per share is a measure of profitability for a company. The earnings per share is calculated by dividing the net income attributable to the common stock by the average number of common shares outstanding. One drawback in using earnings as a profitably measure is that it does not consider the amount of assets needed to generate the earnings. Earning the same profit using fewer assets is more profitable but this is not captured in the earnings per share calculation.
High quality companies will have steadily rising earnings that do not vary greatly through a full business cycle (expansion-recession-expansion). Investing in high quality companies is fairly easy assuming an investor has realistic profit expectations and has the patience to wait for a reasonable stock price relative to the company's value.
Lower quality (cyclical) companies will have earnings that vary greatly over a business cycle. Often these cyclical companies will experience a drastic reduction in earnings during economic recessions. Investment profits can be had with investments in cyclical companies but the timing of the buying and selling of the investment must be in sync with the ebb and flow of the stock market. Typically, the stock market will start to recover about 6 months before the economy comes out of recession. However, this point in time is not obvious in the moment and is only known later with the benefit of hindsight. Furthermore, timing when to sell a cyclical stock is even more difficult. Timing the stock market is a matter of luck so it is best to stick with the higher quality stocks where market timing is not as critical to investing success.
Net Profit Margin:
Medtronic has had net profit margins in the range of 15.7% to 22.8% over the last 10 years with an average net profit margin of 19.8%. The net profit margins have been consistently above 15.0%, which is an indicator of a great company. In the future, we expect Medtronic's net profit margin to hover around its long-term average of about 19.8%.
The net profit margin is net income divided by net revenues. For non-retailing companies, a consistent net profit margin of 7% or higher is an indicator of a good company with some type of durable competitive advantage. In the retailing sector, a net profit margin in the range of 2.5% to 5% is the norm even for the best companies. Ideally, the net profit margin should be steady or rising over the past 10 years.
Return On Assets:
Medtronic has had a return on assets in the range of 10.0% to 14.8% over the last decade. Medtronic's performance in this regard is good considering that the return on assets was above the critical 7.0% level in every year during the period. We expect the return on assets to hover around Medtronic's long-term average return on assets of about 12.3% in the coming decade.
Return on assets is a measure of how much profit is generated from a company's assets independent of how much debt is used to finance the acquisition of those assets. The return on assets is sometimes a better measure of profitability than return on equity because the return on equity can be significantly increased by adding more debt to a company's balance sheet. Adding more debt to a company can inflate profits but comes at the price of a greater risk of bankruptcy.
Measuring profitability using the return on assets does not have this problem because to calculate the return on assets the net income plus the interest expense net of income tax savings is divided by the average total assets of the company. Thus, by dividing the net income (adjusted for the affects of debt financing) by the total assets (debt + equity) of the company cancels out the positive effects of debt.
The return on assets is great for comparing the profitability of companies with different levels of debt in their capital structures. Generally speaking, a consistent return on assets of about 7% or more is a good indication of a good business with some type of durable competitive advantage. One exception to this rule of thumb is the banking sector where a return on assets of just 2% is considered exceptional.
Return On Equity:
Medtronic has had a return on equity in the range of 18.5% to 27.5% during the last 10 years. Medtronic's performance in this area is great considering that the return on equity was above the critical 15% level in every year during the last decade. Also, this is impressive because Medtronic has achieved this performance with a quite manageable amount of debt on its balance sheet. We believe that Medtronic's return on equity will continue at its long-term average of about 21.9% for the foreseeable future.
Return on equity measures a company's performance in financing and using assets to generate earnings. In contrast to the return on assets, the return on equity considers the effect of financing in generating profits. To calculate the return on equity the net income (minus dividends paid on preferred stock) is divided by the average common shareholders' equity. As a rule of thumb, a consistent return on equity of 15% or more (assuming a reasonable level of debt financing) is an indicator of a good company with some type of durable competitive advantage.
A discounted cash flow analysis revealed a fair value for Medtronic shares of $55.61/share. We use the percent of revenue method in our discounted cash flow analysis. The model assumes a weighted average cost of capital (WACC) of 8.5%. Our WACC is calculated using a proprietary formula unique to our firm. A compound annual revenue growth rate of 5.5% is projected over the next 10 years. A compound annual revenue growth rate of 4.0% is assumed for every year thereafter.
Medtronic appears to be a high quality company with an undervalued stock price. Based on a fair value of $55.61/share and the Medtronic closing stock price of $43.88/share (on 02-25-2013) the stock must rise 26.7% to reach fair value.
Disclaimer: Ulfberht Capital is not an investment advisor. This article is not a recommendation to buy or sell securities. Always consult your investment advisor before making any investment decision.